ICER Misses the Numbers That Matter - Alliance for Patient Access

The Institute for Clinical and Economic Review wants to assess the
cost-effectiveness of breakthrough drugs for cystic fibrosis.
But their analysis overlooks key points.

View the Graphic

Tagged Respiratory

Leave a Reply Cancel reply